8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study).

[1]  Jean-Michel Pawlotsky,et al.  EASL Recommendations on Treatment of Hepatitis C 2018. , 2018, Journal of hepatology.

[2]  B. Berkhout,et al.  High Treatment Uptake in Human Immunodeficiency Virus/Hepatitis C Virus–Coinfected Patients After Unrestricted Access to Direct-Acting Antivirals in the Netherlands , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  G. Shiha,et al.  Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt , 2018, Gut.

[4]  C. Boucher,et al.  Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  T. Asselah,et al.  Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4 , 2018, Journal of viral hepatitis.

[6]  T. Asselah,et al.  Eliminating hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6. , 2017, Journal of hepatology.

[7]  M. Buti,et al.  Hepatitis C virus genotype 4: Genotype 1's little brother , 2017, Journal of viral hepatitis.

[8]  T. Asselah,et al.  Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection , 2016, Hepatology.

[9]  S. Hill,et al.  Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis , 2016, PLoS medicine.

[10]  M. Sira,et al.  Hepatitis C genotype 4: The past, present, and future. , 2015, World journal of hepatology.

[11]  B. Grady,et al.  Genetic characterization of multiple hepatitis C virus infections following acute infection in HIV-infected men who have sex with men , 2015, AIDS.